DeSci (Decentralized Science): How Web3 Is Changing Biotech Research

Decentralized science, or DeSci, uses blockchain tools such as DAOs, tokens, and IP-NFTs to fund and share scientific research outside traditional grants and journals. In biotech, the best-known example is VitaDAO, a community-funded longevity group that Pfizer Ventures invested in. The movement is real but small. Two secondary sources count about 50 active projects and more than $60 million in cumulative funding, while the US National Institutes of Health received about $47 billion in base funding for fiscal year 2026. This guide explains how DeSci works, who the main players are, and where the evidence is weak.

What DeSci Tries to Fix

Supporters point to slow grant cycles, paywalled journals, and research that never gets commercialized. A California Management Review article (November 2025) frames DeSci as a possible next frontier of scientific research, while also listing risks: regulation of crypto is “in flux,” and there are data privacy conflicts, scalability problems, and concentrated governance. The case for DeSci is that a global community can fund early-stage ideas that traditional funders skip. The case against is that token markets may reward hype over science.

How It Works: DAOs, Tokens, and IP-NFTs

A DAO, or decentralized autonomous organization, is a group that pools money and votes on how to spend it, using tokens as membership. An IP-NFT, as used by the biotech platform Molecule, is a token that represents rights to research intellectual property, so a community can co-own a project’s potential outcomes. Molecule’s 2025 recap says it has since built a new legal framework that places IP-NFTs inside corporations with equity for qualified contributors, which it calls “IP RWAs” (real-world assets), and that it is integrating with BIO Protocol and pump.science. A brand refresh was planned for the first quarter of 2026. The recap gives no numbers.

VitaDAO: The Flagship

The Block reported in October 2023 that VitaDAO, launched in 2021 as a longevity DAO, had over 10,000 members, 19 funded projects, and about $4 million deployed.

The Pfizer Connection

Pfizer Ventures committed $500,000 in September 2022 and joined a $4.1 million token round in January 2023 alongside Shine Capital, L1 Digital, and Balaji Srinivasan, according to The Block. It was Pfizer’s first DAO investment, held through a special purpose vehicle. VitaDAO’s first spinout biotech, Matrix Biosciences, received $300,000 from VitaDAO and works with Dr. Vera Gorbunova of the University of Rochester on compounds based on naked mole rat hyaluronic acid. Note the distinction: Matrix is a VitaDAO company, and Pfizer is a VitaDAO investor, not a partner of Matrix.

Funding Claims Differ

Sources disagree on how much VitaDAO raised. The Block cites a $4.1 million round, a KuCoin blog says historical raises are about $4.6 million, and the California Management Review says “over $10m through a token sale.” That article lists funded examples, including BE Therapeutics at $100,000, the Korolchuk Lab at $285,000, and Matrix Bio at $300,000. These numbers cannot all be reconciled with the sources available.

BIO Protocol and the BioDAO Wave

Cointelegraph reported on November 8, 2024 that Binance Labs made its first DeSci investment in BIO Protocol, with the amount undisclosed. KuCoin Research’s report says BIO raised over $33 million during its Genesis phase in November 2024, with a 3.32 billion total supply, 20 percent allocated to the Genesis auction, and 5 percent (166 million tokens, vesting over four years) going to Molecule for transferring its core IP and brand to the Bio.xyz Association. It lists BioDAOs including VitaDAO, AthenaDAO, PsyDAO, and ValleyDAO, and an airdrop covering over 8,500 addresses. Those sources are an exchange’s own research pages, so treat the figures cautiously. A claim of a Binance spot listing in 2025 could not be verified, and this article gives no token prices.

Other Projects

ResearchHub, co-founded by Coinbase CEO Brian Armstrong and Patrick Joyce, announced a $5 million seed on June 15, 2023, led by Open Source Software Capital, with angels including Guillermo Rauch, Amjad Masad, and Garry Tan. The Block reported that it pays a token, ResearchCoin, for publishing and peer review. This research found no results data for ResearchHub.

A KuCoin blog from May 1, 2026, which appears machine-translated marketing, claims NanoVita closed a Series A in early April 2026 at a $20 million post-money valuation, and that Sei Foundation’s Sapien Capital fund is $65 million. Given its source, take these as unconfirmed.

How Big Is DeSci, Really?

The California Management Review cites over 50 active DeSci projects (December 2024, citing DWF Labs) and more than $60 million in combined funding, but also a RootData figure of two public funding rounds totaling $11.2 million in one year. The KuCoin blog repeats about 50 projects and over $60 million. Against that, the American Association for Cancer Research reported that Congress provided $47.2 billion in base NIH funding for fiscal 2026, with a cited total of $48.7 billion, rejecting proposed deep cuts, while the fiscal 2027 request is about $41.1 billion. By my own arithmetic, $60 million is roughly 0.13 percent of one year of NIH base funding. DeSci is a rounding error next to public science funding.

What Has Not Been Shown

This research found no verified SEC action against a DeSci project, no shutdown of a major project, and no commentary from Nature or Science. It also found no independently reported scientific result funded by a DeSci group. Absence of evidence is not proof of success or failure, but readers should ask which discoveries, if any, these communities have enabled.

Risks to Weigh

Token prices can swing and may attract speculation instead of scientific interest. Governance can concentrate power in large token holders. Patient or research data on public chains raises privacy questions. Regulation is uncertain. Funding totals are hard to verify. None of this is investment advice, and this article makes no recommendation to buy any token.

Why It Still Matters

Even skeptics can see the appeal of open funding for neglected ideas, faster sharing of results, and rewards for peer review. If a DeSci project produces a drug candidate that passes real trials, the model would gain credibility. Until then, the honest description is an experiment.

How to Evaluate a DeSci Project

Look for named scientists and institutions. Check who owns the intellectual property and how decisions are made. Read the legal structure behind any token. Look for peer-reviewed or independently verified results. Be careful with exchange-published research and promotional posts.

Questions a Critical Reader Should Ask

Who are the scientists behind the project, and are they affiliated with recognized institutions? The Matrix Bio example names Dr. Vera Gorbunova of the University of Rochester, which is the kind of detail to look for. What exactly does the token give holders: voting rights, IP rights, or only speculation? Where does the money go, and how much reaches laboratory work? Has any project published results, entered trials, or produced a licensable asset? The research for this article found no verified results of this kind, which is the central gap in the story.

DeSci and Conventional Funders Together

DeSci does not have to replace traditional funding to be useful. Pfizer Ventures’ investment in VitaDAO shows a conventional pharmaceutical investor experimenting with the model. The Berkeley article frames DeSci as a possible complement for early-stage work. For now, the more realistic role is as a small funder of experimental or neglected ideas next to large public funders, not a substitute for them. If a few projects deliver clear results, the model could grow. If not, it may remain a niche.

A Brief Glossary

A DAO is an online organization governed by token holders who vote on proposals. A BioDAO is a DAO focused on a biotech or health topic, such as VitaDAO for longevity, AthenaDAO, PsyDAO, and ValleyDAO, as listed in the KuCoin report. An IP-NFT is a token tied to rights in research intellectual property. A spinout is a company created from a funded project, like Matrix Bio. A launchpad is a platform that helps projects issue tokens, which is how the sources describe BIO Protocol. A special purpose vehicle is a legal entity formed for a specific investment, as Pfizer Ventures used for its VitaDAO holding.

How Traditional Funding Compares

Traditional science funding runs through government agencies, universities, foundations, and companies, with peer review and long timelines. The NIH figures show the scale: $47.2 billion in base funding for fiscal 2026 according to AACR, with Congress rejecting proposed deep cuts and the next request at about $41.1 billion. Those numbers also show how exposed science is to political decisions, which supporters of DeSci cite as a reason for alternatives. Critics respond that tokens introduce a different exposure, to markets. Neither side has proven its case, and the available evidence is limited.

What Would Make DeSci Credible

Three things would help: independent verification of funding totals, published results from funded projects, and clarity on legal structures. The Molecule recap’s move toward corporate equity structures suggests the field is already adjusting to legal realities. If a funded project reports clinical or laboratory milestones that others can check, skeptics will have a reason to pay attention. Until then, treat claims with the same scrutiny you would give any early-stage research.

Who This Matters To

Researchers might use DeSci as an additional funding route for ideas that struggle to win grants. Investors might see it as speculative exposure, with the risks above. Patients and advocacy groups might see community funding for neglected conditions. Journalists and policy makers might watch for regulatory moves, although no SEC action was verified for this article. Each audience should read the sources, not the marketing.

What the Numbers Do and Do Not Show

The funding figures in this article illustrate the problem of verification. A cumulative figure of $60 million, a one-year figure of $11.2 million, a $4.1 million round, and a $33 million token event all appear in sources of different quality, and some come from exchanges with a commercial interest in token activity. As of November 9, 2026, a fresh search found no newly verified funded result, regulatory action or major journal commentary, and the funding figures remain the same. The most credible numbers here come from The Block’s reporting on identifiable rounds and from AACR’s summary of NIH appropriations. Treat the rest as claims. This is a normal feature of a young sector, and it is why this article keeps the language cautious.

Where the Pfizer Story Fits

Headlines that link Pfizer to decentralized science can mislead if read quickly. The Block’s report says Pfizer Ventures invested in VitaDAO’s token round through a special purpose vehicle. It does not say Pfizer is partnering on drug development with Matrix Bio or any other DAO project. The investment was described as Pfizer’s first DAO investment, which is a notable signal of interest, not evidence of scientific validation. Reading carefully matters in this sector, where promotional language is common.

Frequently Asked Questions

What is DeSci?

Decentralized science, which uses blockchain tools such as DAOs and tokens to fund and share research.

Did Pfizer invest in DeSci?

Pfizer Ventures invested in VitaDAO, committing $500,000 in September 2022 and joining a $4.1 million round in January 2023.

How big is DeSci funding?

Secondary sources cite about 50 projects and over $60 million, though another figure says $11.2 million in two rounds in a year.

What is an IP-NFT?

A token representing rights to research intellectual property, used by Molecule.

Is DeSci a replacement for the NIH?

No. NIH base funding for fiscal 2026 was $47.2 billion.

References and Sources

The Block, “Pfizer-backed DAO launches community-funded biotech firm”: https://www.theblock.co/post/255164/pfizer-backed-dao-launches-community-funded-biotech-firm

California Management Review, “Can Decentralized Science Be the Next Frontier of Scientific Research”: https://cmr.berkeley.edu/2025/11/can-decentralized-science-be-the-next-frontier-of-scientific-research/

KuCoin Blog, “AE DeSci, AI or Meme: where crypto capital flows in mid-2026”: https://www.kucoin.com/ru/blog/ae-desci-ai-or-meme-where-crypto-captial-flows-in-mid-2026

Cointelegraph, “Binance Labs invests in BIO Protocol”: https://cointelegraph.com/news/binance-labs-invests-in-bio-protocol

KuCoin Research, “BIO Protocol (BIO)”: https://kucoin.com/research/project-reports/bio-protocol-bio

Molecule, “Molecule Wrapped”: https://moleculeto.substack.com/p/molecule-wrapped

The Block, “Scientists can earn crypto as Brian Armstrong startup raises $5 million”: https://www.theblock.co/amp/post/234960/scientists-can-earn-crypto-as-brian-armstrong-startup-raises-5-million

AACR, “Cancer Policy Monitor: April 14, 2026”: https://www.aacr.org/professionals/policy-and-advocacy/aacr-cancer-policy-monitor/cancer-policy-monitor-april-14-2026/

About The Author

Written By

I write about AI, Web3, Crypto, Fintech, and the technologies shaping the digital economy. Connect with me on LinkedIn: https://www.linkedin.com/in/kenneth-onyebuchi-3b4634228

More From Author

Leave a Reply

You May Also Like

Top Global Startup Founders Disrupting Tech in 2026

Top Global Startup Founders Disrupting Tech in 2026

The founders shaping tech in 2026 are mostly building AI companies: Dario Amodei at Anthropic,…

Future of Work 2026: How AI Automation Is Affecting Tech Careers

Future of Work 2026: How AI Automation Is Affecting Tech Careers

AI is changing tech careers, but the data does not show a collapse. It shows…

SpaceX Starship Commercial Payloads and the Mars Flight Schedule in 2026

SpaceX Starship Commercial Payloads and the Mars Flight Schedule in 2026

As of November 9, 2026, there is no Starship Mars flight on any confirmed schedule,…